Marshall Wace, LLP Cidara Therapeutics, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.01 - $1.42 $61,661 - $86,692	61,051 Added 216.0%	89,315 $100,000
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $21,198 - $55,962	28,264 New	28,264 $35,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.39 $98,093 - $203,507	-146,408 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.18 - $2.18 $44,390 - $82,009	-37,619 Reduced 20.44%	146,408 $185,000
Q3 2021 Nov 15, 2021	BUY	$1.48 - $2.35 $272,359 - $432,463	184,027 New	184,027 $412,000

Q1 2020 May 15, 2020	SELL	$1.74 - $4.26 $68,910 - $168,713	-39,604 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.77 - $3.84 $70,099 - $152,079	39,604 New	39,604 $152,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.